Brean Murray Carret & Co. Starts Ventrus Biosciences (VTUS) at Buy; Strong Clinical Data Weeks Away
Tweet Send to a Friend
Brean Murray Carret & Co. initiates coverage on Ventrus Biosciences (NASDAQ: VTUS) with a Buy. PT $30.00.
Analyst, Jonathan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Jonathan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
